Hemogenyx Pharmaceuticals PLC Announces Final Results

Rhea-AI Summary

Hemogenyx Pharmaceuticals (LSE: HEMO), a biopharmaceutical company focused on blood disease treatments, has released its final audited results for the year ending December 31, 2024. The company achieved several significant milestones including:

• Initiation of Phase I clinical trials for their HG-CT-1 product candidate
• Continued development of their Chimeric Bait Receptor antiviral/biodefence platform, which received recognition at major conferences
• Successful fundraising of £3.9 million through new ordinary shares in 2024
• Additional funding of £1.3 million secured in early 2025

The complete annual report is accessible on the company's website at hemogenyx.com.

LONDON, UNITED KINGDOM / ACCESS Newswire / April 28, 2025 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces its final audited results for the year ended 31 December 2024. The Annual Report is available to view on the Company's website at https://hemogenyx.com/.

Key Highlights

• The Company commenced Phase I clinical trials of its HG-CT-1 product candidate.

• Continuing development of Chimeric Bait Receptor antiviral/biodefence platform, which gained attention at major conferences.

• Successfully raised £3.9 million (before expenses) through the allotment and issue of new ordinary shares during the year ended 31 December 2024, and a further £1.3 million in early 2025.

Fuller details of these developments are contained in the full, unedited text of the final results for the year ended 31 December 2024 below.

http://www.rns-pdf.londonstockexchange.com/rns/3187G_1-2025-4-25.pdf

Enquiries:

Hemogenyx Pharmaceuticals plc	https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder	headquarters@hemogenyx.com
Peter Redmond, Director	peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP	Tel: +44 (0)20 3470 0470
Matthew Johnson, Vadim Alexandre, Adam Cowl
Peterhouse Capital Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey, Charles Goodfellow

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Hemogenyx Pharmaceuticals PLC

View the original press release on ACCESS Newswire

FAQ

What major milestones did Hemogenyx Pharmaceuticals (HOPHF) achieve in 2024?

In 2024, Hemogenyx started Phase I clinical trials for HG-CT-1, advanced their Chimeric Bait Receptor platform, and raised £3.9 million through share issuance.

How much funding did Hemogenyx Pharmaceuticals (HOPHF) secure in 2024-2025?

Hemogenyx raised £3.9 million through share issuance in 2024 and an additional £1.3 million in early 2025, totaling £5.2 million.

What is the current stage of Hemogenyx's HG-CT-1 drug development?

HG-CT-1 has entered Phase I clinical trials as of 2024, marking its transition from preclinical to human testing phase.

What therapeutic areas is Hemogenyx Pharmaceuticals (HOPHF) focusing on?

Hemogenyx focuses on developing new therapies and treatments for blood diseases, including their HG-CT-1 product and Chimeric Bait Receptor platform.